Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) EBIT Margin (2018 - 2025)

Dna X filings provide 8 years of EBIT Margin readings, the most recent being 24.55% for Q3 2025.

  • On a quarterly basis, EBIT Margin fell 873.0% to 24.55% in Q3 2025 year-over-year; TTM through Sep 2025 was 3.15%, a 2290.0% increase, with the full-year FY2024 number at 6.09%, down 664.0% from a year prior.
  • EBIT Margin hit 24.55% in Q3 2025 for Dna X, up from 60.16% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 110.91% in Q4 2024 to a low of 74.23% in Q3 2021.
  • Median EBIT Margin over the past 5 years was 24.55% (2025), compared with a mean of 23.83%.
  • The widest YoY moves for EBIT Margin: up 12026bps in 2024, down -5897bps in 2024.
  • Dna X's EBIT Margin stood at 73.71% in 2021, then skyrocketed by 94bps to 4.39% in 2022, then crashed by -113bps to 9.34% in 2023, then soared by 1287bps to 110.91% in 2024, then tumbled by -122bps to 24.55% in 2025.
  • The last three reported values for EBIT Margin were 24.55% (Q3 2025), 60.16% (Q2 2025), and 3.86% (Q1 2025) per Business Quant data.